Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ceralasertib by AstraZeneca for Metastatic Colorectal Cancer: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ceralasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Ceralasertib by AstraZeneca for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Ceralasertib is under clinical development by AstraZeneca and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Ceralasertib?
Ceralasertib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According...